Experiment Analysis & Result Interpretation Questions

Reading out an experiment after it runs: interpreting the treatment effect, deciding ship/no-ship, and reconciling conflicting or flat results. Covers reasoning under uncertainty, acting on inconclusive or limited data, and translating a measured effect into a business decision. The emphasis is turning experiment output into a defensible recommendation.

MediumTechnical

64 practiced

When reporting experiment results, when would you prefer confidence intervals over p-values? Describe how you would present both in a dashboard tile for product managers and executives, and how to interpret wide vs narrow intervals in the context of decision-making.

HardTechnical

54 practiced

Explain challenges when analyzing ratio metrics such as average revenue per user (ARPU) or revenue per paying user. Cover issues with distributions (heavy tails), outliers, bias in ratio estimators, and approaches for confidence intervals (delta method, bootstrap). Recommend practical approaches a BI analyst can use in production reporting.

Sample Answer

Key issues with ratio metrics (ARPU, revenue per paying user)- Heavy-tailed distributions: revenue is often skewed; a few users generate most revenue. The mean (ARPU) is sensitive to tail behavior and may not represent "typical" users.- Outliers: single big transactions inflate ARPU and widen uncertainty; removal or capping changes interpretation.- Bias in ratio estimators: E[X/Y] ≠ E[X]/E[Y] when computing aggregated ratios from grouped sums or averages; naively averaging per-user ratios vs. total-revenue/total-users can produce different, biased results depending on sampling and grouping.

Inference and CI approaches- Delta method: analytic, fast. Linearizes the ratio r = X/Y around expectations to approximate Var(r) ≈ (1/μY^2)Var(X) + (μX^2/μY^4)Var(Y) − 2μX/(μY^3)Cov(X,Y). Works well for large samples and light tails but underestimates variance for heavy-tailed revenue.- Bootstrap: resampling users (not events) to empirically build CI for ARPU. Handles skewness and complex estimators; use percentile or bias-corrected CIs. Requires enough unique users and compute but is robust.- Robust alternatives: report median revenue per user or trimmed means (e.g., 95% trimmed mean) and use quantile CIs (bootstrap) for skewed distributions.

Practical production recommendations for a BI analyst- Prefer event-level aggregation to compute ARPU as total_revenue/total_users for population-level metric; avoid averaging group-level rates unless intentional.- Complement ARPU with distributional metrics: median, 90th/99th percentiles, Gini or Lorenz share of top 1%/5%, and counts of high-value users.- Apply winsorization or top-capping for trend monitoring; always disclose the capping policy in dashboards.- Use bootstrap (user-level) to produce CIs for dashboards where compute allows; otherwise use delta method but add a caveat about heavy tails.- Automate anomaly detection on both ARPU and distributional indicators (e.g., sudden rise in top-1% share).- Documentation: show formulas, sample sizes, handling of refunds/chargebacks, and any outlier rules so stakeholders interpret ARPU correctly.

Summary: treat ARPU as a population-level ratio with heavy-tail-aware inference; show complementary robust statistics and transparent outlier handling; use bootstrap for accurate CIs in production when feasible.

EasyTechnical

44 practiced

Differentiate between reporting absolute change and relative lift when presenting feature results. Provide two situations where executives prefer absolute numbers and two where product managers prefer relative lifts. Show how you would present both in a short executive slide or dashboard tile.

MediumTechnical

48 practiced

You're asked to present an ambiguous experiment result: treatment shows a positive but non-significant uplift (p=0.12) with low power. How would you present this to an executive team and recommend next steps? Include what additional analyses or experiments you'd propose and how to quantify uncertainty in your recommendation.

Sample Answer

Situation: We ran an A/B test of a new treatment. The uplift in the primary metric was positive but non-significant (p = 0.12) and post-hoc power is low — so the data are inconclusive rather than evidence of no effect.

Recommendation to executives (clear, non-technical):- The point estimate suggests potential upside, but statistical evidence is weak due to insufficient sample size/noise. I do not recommend a full rollout yet; instead, pursue targeted follow-ups to reduce uncertainty while minimizing business risk.

What I'll present (visual + verbal):- Point estimate with 95% confidence interval and a simple interpretation: “Estimated uplift = +X% (95% CI: -Y% to +Z%).”- Power/MDE summary: show achieved power and the minimum detectable effect (MDE) at our sample size.- Expected Value analysis: combine the point estimate with business impact (revenue per user, cost of rollout) to show expected gain/loss under uncertainty.

Proposed next analyses and experiments:1. Variance reduction: re-examine metric definition, filter noisy segments, use covariate adjustment (ANCOVA) or CUPED to improve sensitivity.2. Pre-specified subgroup analysis: test high-value cohorts where treatment could be stronger (but pre-register to avoid p-hacking).3. Extend the experiment or run an additional A/B test sized to detect a realistic MDE (power calc: choose MDE based on business thresholds, e.g., 80% power at α=0.05).4. Sequential or Bayesian approach: consider a Bayesian analysis to report a credible interval and probability uplift > business threshold (e.g., P(uplift > 1%) = 72%).5. Funnel / leading indicators: examine upstream metrics (engagement, add-to-cart) for earlier signal and consistency.

Quantifying uncertainty in recommendation:- Report confidence intervals and probability of beating the business-significant threshold (via Bayesian posterior or bootstrap).- Provide expected value of two actions (rollout vs. more testing): EV = P(success)*benefit - P(failure)*cost, showing break-even probabilities.- Recommend decision rule tied to business tolerance (e.g., only roll out if P(uplift > MDE) > 90% or EV positive).

Next steps I’d take this week:- Deliver a one-page executive slide with CI, MDE/power, EV table, and 2 recommended options (extend & optimize test vs. targeted pilot).- If they prefer quicker learning, run a scaled pilot in top 10% of users with improved metric and covariate adjustment; otherwise, scope a full-powered follow-up test.

This balances honest communication of uncertainty, practical next steps to reduce noise, and a business-driven decision framework.

MediumBehavioral

61 practiced

Describe a time you had to recommend stopping an experiment early due to safety, business risk, or ethical concerns while stakeholders wanted to continue. Explain how you evaluated the evidence, how you communicated the decision and its implications, and how you documented the decision for audit and learning purposes. If you have no real example, outline how you would handle such a scenario.

Sample Answer

Situation: I was supporting a pricing experiment dashboard for a retail product that showed a strong uplift in conversion and revenue. Stakeholders wanted to expand the experiment to more markets immediately, but I found patterns that suggested the uplift might be driven by disproportionate impact on specific demographic groups — potentially discriminatory pricing — which posed legal, ethical, and reputational risk.

Task: My responsibility was to assess whether the experiment signals were valid and safe to scale, and to recommend whether we should stop the experiment.

Action:- Evaluated the evidence: I ran cohort breakdowns (age, ZIP, device, returning vs new customers), checked randomization balance, re-ran statistical tests with multiple-hypothesis correction, and reviewed data lineage to rule out instrumentation errors. The uplift persisted but was concentrated in a few protected-region ZIPs and new-customer cohorts; randomization was skewed due to a rollout script bug.- Assessed risk: I consulted compliance/legal with initial findings and produced a concise risk matrix quantifying legal, customer trust, and revenue impacts if continued.- Communicated the decision: I prepared a one-page executive summary and a short deck with clear visuals: the cohort charts, imbalance evidence, and p-values. In a stakeholder meeting I explained why the skew invalidated causal claims and the potential harms of scaling. I recommended pausing the rollout, rolling back the pricing change for affected cohorts, and running a controlled re-randomized test after fixes.- Implemented documentation: logged the decision and evidence in our experiment tracking system (with links to raw datasets, SQL queries, dashboard versions), filed a ticket for engineering to fix the randomization bug, and wrote a postmortem capturing timeline, root cause, decisions, and learnings.

Result: Stakeholders accepted the pause once the risk and data issues were clear. Engineering fixed the rollout logic, we re-randomized and re-ran the experiment with pre-registered analysis, and subsequent results showed a smaller, non-discriminatory uplift. The audit trail and postmortem were used in quarterly compliance review and informed a new checklist for experiment rollout.

What I learned: Present clear, quantified evidence, map risks to business outcomes, involve compliance early, and document everything so decisions are auditable and future experiments are safer.

Unlock Full Question Bank

Get access to hundreds of Experiment Analysis & Result Interpretation interview questions and detailed answers.

Join thousands of developers preparing for their dream job.